Uremia is not curable and requires renal replacement therapy. The average life span of hemodialysis and peritoneal dialysis is about 15 years. However, individual differences are obvious, some patients may only survive less than a year, some patients may even survive for decades, and the average survival time of kidney transplant patients is about 10-20 years, which cannot be generalized. Uremic stage is the end stage of all kidney diseases, and it cannot be cured by applying drugs at this stage. Only through hemodialysis or peritoneal dialysis, which is a form of renal replacement therapy, can the patient’s clinical symptoms be relieved. Patients with uremia can undergo kidney transplantation. In addition to renal replacement therapy, drugs must be applied to actively treat the complications of uremia. For example, patients with anemia need oral iron and subcutaneous injection of erythropoietin, patients with hypertension need oral blood pressure-lowering drugs such as valsartan and nifedipine extended-release tablets, patients with calcium-phosphorus metabolism dysregulation need oral calcium and calcitriol, etc., and patients with post renal transplantation need oral anti-rejection drugs. In general, the average life span of hemodialysis and peritoneal dialysis is about 15 years, and the average survival of kidney transplant patients is about 10~20 years. Currently, some data show that hemodialysis patients can live up to 40 years; kidney transplant patients can even live more than 30 years. However, if the patient is not treated in time and combined with heart failure, cerebrovascular disease, rejection reaction, etc., he may die within one year. Uremia patients are recommended to consult regular hospitals, standardized treatment under the guidance of physicians, to maximize the survival of patients.